Pharmacological options for Motion Sickness in children

Motion Sickness (MS) increases its epidemiological weight due to greater willingness to travel and to the diffusion of cinematic videos, video games and virtual reality technologies with strong kinetic stimuli. On the other hand, the pathophysiological mechanisms are identified as a sensory mismatch between vestibular, visual and proprioceptive inputs, and are not well understood. This sensory mismatch is particularly present in the pediatric age, also due to non-contemporary development and maturation times of these receptors/analyzers. On this basis, drug therapy for these patients has a purpose predominantly symptomatic and/or preventive. For paediatric age it deserves further study, since limited experiences exist in the literature and therapeutic choices are often based on experiences in an adult population. In this work we report the main drugs and nutraceuticals that can be used for MS, about the indication and doses for the paediatric age, with the most recent considerations in the literature.